Document Preview Unavailable

Genomic heterogeneity at baseline is associated with T790M resistance mutations in EGFR‐mutated lung cancer treated with the first‐/second‐generation tyrosine kinase inhibitors

Menzel, Michael; Kirchner, Martina; Kluck, Klaus; Ball, Markus; Beck, Susanne; et al.  The Journal of Pathology: Clinical Research Vol. 10, Iss. 2,  (Mar 1, 2024).

You might have access to this document